Literature DB >> 11755145

Species-related pharmacological heterogeneity of histamine H(3) receptors.

L Ireland-Denny1, A S Parihar, T R Miller, C H Kang, K M Krueger, T A Esbenshade, A A Hancock.   

Abstract

We compared radioligand binding and functional data for histamine H(3) receptor ligands across different tissues or species to evaluate the basis for pharmacological evidence of receptor heterogeneity previously reported. Agonist binding affinities showed correlation coefficients near unity in comparing human, dog, rat, and guinea pig cerebral cortical histamine H(3) receptors. Antagonist binding affinities revealed lower correlations for human compared to dog, rat, or guinea pig, suggesting species-based pharmacological differences. The functional potencies of histamine H(3) receptor antagonists in field-stimulated guinea pig ileum were highly correlated to binding affinities for guinea pig, dog, and, to a lesser extent, rat cerebral cortex. However, antagonist binding affinity at human cerebral cortex did not correlate well with guinea pig ileum functional potency. These results suggest significant interspecies histamine H(3) receptor heterogeneity, consistent with recent receptor gene sequence data. Therefore, genetic heterogeneity, rather than peripheral and central histamine H(3) receptor diversity, is responsible for the pharmacological differences observed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11755145     DOI: 10.1016/s0014-2999(01)01518-7

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  9 in total

1.  Compared pharmacology of human histamine H3 and H4 receptors: structure-activity relationships of histamine derivatives.

Authors:  Florence Gbahou; Ludwig Vincent; Marie Humbert-Claude; Joel Tardivel-Lacombe; Claude Chabret; Jean-Michel Arrang
Journal:  Br J Pharmacol       Date:  2006-04       Impact factor: 8.739

2.  Selective expression of histamine receptors H1R, H2R, and H4R, but not H3R, in the human intestinal tract.

Authors:  L E Sander; A Lorentz; G Sellge; M Coëffier; M Neipp; T Veres; T Frieling; P N Meier; M P Manns; S C Bischoff
Journal:  Gut       Date:  2005-11-18       Impact factor: 23.059

Review 3.  CB2 Cannabinoid receptors as a therapeutic target-what does the future hold?

Authors:  Amey Dhopeshwarkar; Ken Mackie
Journal:  Mol Pharmacol       Date:  2014-08-08       Impact factor: 4.436

4.  Samelisant (SUVN-G3031), a potent, selective and orally active histamine H3 receptor inverse agonist for the potential treatment of narcolepsy: pharmacological and neurochemical characterisation.

Authors:  Ramakrishna Nirogi; Vijay Benade; Saivishal Daripelli; Ramkumar Subramanian; Venkatesh Kamuju; Gopinadh Bhyrapuneni; Nageswara Rao Muddana; Venkat Reddy Mekala; Surendra Petlu; Pradeep Jayarajan; Rajesh Badange; Anil Shinde; Venkat Jasti
Journal:  Psychopharmacology (Berl)       Date:  2021-02-07       Impact factor: 4.530

5.  The interaction of escitalopram and R-citalopram at the human serotonin transporter investigated in the mouse.

Authors:  Jacob P R Jacobsen; Per Plenge; Benjamin D Sachs; Alan L Pehrson; Manuel Cajina; Yunzhi Du; Wendy Roberts; Meghan L Rudder; Prachiti Dalvi; Taylor J Robinson; Sharon P O'Neill; King S Khoo; Connie Sanchez Morillo; Xiaodong Zhang; Marc G Caron
Journal:  Psychopharmacology (Berl)       Date:  2014-05-09       Impact factor: 4.530

6.  Histamine excites neurones in the human submucous plexus through activation of H1, H2, H3 and H4 receptors.

Authors:  Eva Breunig; Klaus Michel; Florian Zeller; Stefan Seidl; Claus Werner Hann v Weyhern; Michael Schemann
Journal:  J Physiol       Date:  2007-07-12       Impact factor: 5.182

7.  Histamine h3 receptor: a novel therapeutic target in alcohol dependence?

Authors:  Saara Nuutinen; Jenni Vanhanen; Tiia Mäki; Pertti Panula
Journal:  Front Syst Neurosci       Date:  2012-05-18

8.  Global analysis of small molecule binding to related protein targets.

Authors:  Felix A Kruger; John P Overington
Journal:  PLoS Comput Biol       Date:  2012-01-12       Impact factor: 4.475

9.  Oncostatin M Confers Neuroprotection against Ischemic Stroke.

Authors:  Sen Guo; Zuo-Zhi Li; Jun Gong; Mei Xiang; Peng Zhang; Guang-Nian Zhao; Mingchang Li; Ankang Zheng; Xueyong Zhu; Hao Lei; Tanaka Minoru; Hongliang Li
Journal:  J Neurosci       Date:  2015-08-26       Impact factor: 6.167

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.